Top Industry Leaders in the ADHD Therapeutics Market
Latest ADHD Therapeutics Companies Updates:
This US-based company is preparing to submit a New Drug Application (NDA) for its once-daily ADHD medication, CTx-1301, by mid-2024.CTx-1301 uses Cingulate's innovative Precision Timed Release (PTR) technology to deliver three timed doses of dexmethylphenidate throughout the day, potentially improving patient adherence and reducing side effects.Positive top-line results from Phase III trials in adults have already been announced, with pediatric and adolescent trials slated for August 2023.
ABVC, a clinical-stage biopharmaceutical company, secured a US patent for the use of PDC-1421, a Radix Polygala extract, in its ADHD drug ABV-1505.ABV-1505 acts as a Norepinephrine Transporter (NET) inhibitor, a novel approach to treating ADHD with fewer side effects than traditional stimulants.Phase IIa trials have shown promise, with Phase IIb results expected by year-end, potentially positioning ABVC for a unique entry into the market.
List of ADHD Therapeutics Key companies in the market:
- Advanz Pharmaceutical (Canada)
- Eli Lilly and Company (US)
- Highland Therapeutics Inc. (Canada)
- Janssen Pharmaceuticals, Inc. (Belgium)
- NEOS Therapeutics, Inc. (US)
- Pfizer Inc. (US)
- Novartis AG (Switzerland)
- Noven Pharmaceuticals, Inc. (US)